Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
  • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
  • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
  • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
  • A01N43/80—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/42—Oxazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/02—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • A61K47/38—Cellulose; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
  • A61P33/14—Ectoparasiticides, e.g. scabicides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

• Isoxazoline compounds are known in the art and these compounds and their use as antiparasitic are described, for example, in US patent application US 2007/0066617, and International Patent applications WO 2005/085216, WO 2007/079162, WO
• isoxazoline compounds are carbamoyl benzamide phenyl isoxazoline (CBPI) compounds.
• CBPI carbamoyl benzamide phenyl isoxazoline
• a specific example of a CBPI compound is 4-[5-(3,5- Dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-2-methyl-N-[(2,2,2-trifluoro- ethylcarbamoyl)-methyl]-benzamide (CAS RN [864731 -61 -3]) - USAN fluralaner.
• the CBPI compound fluralaner is disclosed in patent application WO 2005/085216.
• Bravecto® is a chewable tablet which contains fluralaner approved for the treatment and prevention of flea infestations and the treatment and control of tick infestations in dogs (see NADA 141 -426, May 15, 2014).
• Crystallization is a commonly used technique for the purification of chemical and pharmaceutical substances. It is a separation technique in which solids are separated from a solution. When a solid substance (solute) is mixed with a liquid solvent and stirred, the solute dissolves in the solvent to form a solution. As more and more solute is added to the solvent, a point comes after which no more solute can be dissolved in the solvent.
• the solution is called a saturated solution.
• the amount of solute that can dissolve in the solvent is a function of temperature. As the temperature of the solvent is increased, the amount of solute that can be dissolved increases. When the heated saturated solution is cooled, some of the dissolved solute comes out of the solution and crystals of solute start to form. The size of crystals formed during this process depends on the cooling rate. If the solution is cooled at a fast rate then, it forms tiny crystals in large numbers. Large crystals are formed at slow cooling rates, (see “Crystallization: Separation of Substances" October 31 , 2017, https://byjus.com/chemistry/crystallization/ accessed December 19, 2017).
• T ring structure: 5-, or 6-membered, or bicyclic, which is optionally substituted by one or more radicals Y;
• Q X-NR 3 R 4 , NR 5 -NR 6 -X-R 3 , X-R 3 , or a 5-membered N-heteroaryl ring, which is optionally substituted by one or more radicals;
• haloethylaminocarbonylmethyl haloethylaminocarbonylethyl, tetrahydrofuryl, methylaminocarbonylmethyl, (N,N-dimethylamino)-carbonylmethyl,
• alkylsulfanylalkyl alkylsulfinylalkyl, alkylsulfonylalkyl, cycloalkyl,
• Z A hydrogen, halogen, cyano, or halomethyl (CF 3 );
• R 4 hydrogen, ethyl, methoxymethyl, halomethoxymethyl, ethoxymethyl,
• haloethoxymethyl propoxymethyl, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cydopropylcarbonyl, methoxycarbonyl, methoxymethylcarbonyl, aminocarbonyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl,
• R 5 H, alkyl, or haloalkyl
• R 6 H, alkyl, or haloalkyl; or wherein R 3 and R 4 together form a substituent selected from the group consisting of:
• An isoxazoline compound particle composition comprising particles with a thickness of greater than 10 ⁇ , preferably greater than 20pm as measured by scanning electron microscopy (SEM), and a mechanical resiliency as measured by a pressure titration using the Sympatec HELOS, wherein the particle size distribution (d50) of the particles does not decrease by more than 40% from 1 to 3 bar dispersion pressure.
• FIG. 2 Temperature dependence of the solubility of fluralaner in isopropanol (IPA).
• Figure 3 a schematic diagram of the crystallizer vessel and the other components of the system.
• FIG. 5 Pressure titration of fluralaner crystals not produced by the inventive process.
• Sympatec Pressure Titration as pressure increased from 1 -3 bar, particle size (d50) decreases from 50 ⁇ to 25 ⁇ . Material made from non optimized recirculation process. In this case, the crystals are thin, and not mechanically robust, as can be seen from the pressure titration experiment where between 1 bar dispersing pressure and 3 bar dispersing pressure, the x50 is reduced from 1 10um at 1 bar, to 80um at 2bar to 60 at 3bar, or 46% reduction in size from 1 bar to 3bar.
• Figure 6 Particle size distribution and pressure titration of fluralaner crystals produced by the inventive process. Sympatec Pressure Titration: as pressure increased from 1 -3 bar, particle size (d50) decreases from 100um to 73um.
• Figure 7 Particle size distribution and pressure titration of fluralaner crystals produced by the inventive process.
• Figure 8 - is a SEM image of fluralaner crystals produced by a process that is not the inventive process.
• Figure 10 Particle size distribution of the material made from Example 3. Resulting material had an x50 of 108, and an approximately 24% reduction in x50 from the pressure titration from 1 bar to 3bar.
• FIG. 12 Schematic of the pilot scale equipment used in Example 4.
• Figure 13 Particle size distribution of the material made from Example 4. Resulting material had an d50 of 103 ⁇ , and d10 of 47.3 ⁇ and an d90 of 158.8 ⁇ .
• Figure 15 Particle size distribution of the material made from Example 5. Resulting material had an average d50 of 99 ⁇ , and an approximately 20% reduction in d50 from the pressure titration from 1 bar to 3bar.
• An improved process to produce large isoxazoline compound particles which comprises initiating crystallization and then maintaining the temperature of the crystallization in the metastable region by removing, reheating and recycling a portion of the solvent thereby allowing the existing crystals to grow larger while minimizing the formation of newer smaller crystals.
• nucleation is initiated by nucleation, which happens either spontaneously or is induced by vibration or seed particles. Nucleated crystals are small crystals formed when there is a drop in the temperature of a saturated solution. If nucleation sets in too quickly, too many too small crystals will grow.
• the seed crystals are typically less than 10 ⁇ length.
• the process of crystallization starts with the addition of nucleated material (seed crystals) to a solution of isoxazoline compound in solution to achieve surface properties of the starting crystals that are amenable to growth.
• seed crystals seed crystals
• a slurry of isoxazoline compound particles in the solvent is formed. This initial slurry is kept at a relatively high temperature (52-54°C) to facilitate reasonable growth rates and avoid further nucleation. At lower temperatures, growth rates are significantly slower, and the risk of nucleation is greater.
• a portion of the batch of isoxazoline compound particle slurry is removed, heated to dissolve any crystals that have formed and returned to the crystallizer to provide continuous supersaturation to drive crystal growth.
• This recycle rate cannot be too low slow since under these growth conditions thin plates are preferentially formed, which are susceptible to breakage.
• the recycle rate cannot be too high, since under these conditions either nucleation, or aggregation can occur.
• the crystallizer is cooled to about 0°C, preferable about -10°C over 10-48 hours, preferably 12-20 hours to further relieve supersaturation and achieve growth to the desired dimensions.
• compositions comprising particles of isoxazoline compounds with a defined particle size produced by the inventive process show desirable bioavailability and duration of efficacy, while causing minimal irritation at the injection site.
• Such compositions also provide desirable safety profiles toward the warmblooded and bird animal recipients.
• a single administration of such compositions generally provides potent activity against one or more parasites (e.g., ectoparasites, e.g. fleas, ticks or mites), while also tending to provide fast onset of activity, long duration of activity, and/or desirable safety profiles.
• parasites e.g., ectoparasites, e.g. fleas, ticks or mites
• Scanning electron microscopy is an analytical instrument that uses a focused beam of high-energy electrons to generate a variety of signals at the surface of solid specimens.
• the signals reveal information about the sample including external morphology (texture), chemical composition, and crystalline structure and orientation of materials making up the sample.
• Solvent with temperature dependent solubility for the solute means that the solubility of the solute in the solvent varies with temperature. Generally, this means the solubility increases with increased temperature. Temperature sensitivity of fluralaner solubility in isopropanol (IPA) is shown in Figure 1 with the x-axis showing temperature and the y-axis showing the solubility of fluralaner in expressed in mg/ml_. The meta-stable region of the solubility temperature curve is the region where existing crystals will grow, but no new crystals are formed.
• IPA isopropanol
• Crystallizer vessel is a vessel in which crystallization occurs.
• Saturation is the state of a solution when it holds the maximum equilibrium quantity of dissolved matter at a given temperature.
• Slurry is a thin suspension.
• Batch is the solvent plus solute.
• Batch volume is the volume of the batch.
• particle size data reported are volume weighted as measured by conventional particle techniques well known to those skilled in the art, such as static light scattering (also known as laser diffraction), image analysis or sieving. More discussion of particle size measurement is provided below.
• Mechanical resiliency is the resistance of crystals or particles to break into smaller crystals or particles when exposed to pressure or stress from other sources.
• T is selected from
• the radical Y hydrogen, halogen, methyl, halomethyl, ethyl, or haloethyl.
• Q is selected from
• an isoxazoline for use in the invention is the compound: (Formula 2) wherein R a , R 1b , R 1c are independently from each other: hydrogen, CI or CF 3 .
• R 1a and R c are CI or CF 3
• R 1b is hydrogen
• R 3 is H
• R 4 is: -CH 2 -C(O)- NH-CH2-CF3, -CH 2 -C(0)-NH-CH 2 -CH 3 , -CH 2 -CH 2 -CF 3 or -CH 2 -CF 3 .
• the isoxazoline for use in the invention also includes pharmaceutically acceptable salts, esters, and/or N-oxides thereof.
• the reference to an isoxazoline compound refers equally to any of its polymorphic forms or stereoisomers.
• the pharmaceutical composition according to the invention may employ a racemic mixture of an isoxazoline for use in the invention, containing equal amounts of the enantiomers of such isoxazoline compound as described above.
• the pharmaceutical composition may use isoxazoline compounds that contain enriched stereoisomers compared to the racemic mixture in one of the enantiomers of the isoxazoline as defined herein.
• the pharmaceutical composition may use an essentially pure stereoisomer of such isoxazoline compounds.
• Such enriched- or purified stereoisomer preparations of an isoxazoline for use in the invention may be prepared by methods known in the art. Examples are chemical processes utilizing catalytic asymmetric synthesis, or the separation of diastereomeric salts (see e.g.: WO 2009/063910, and JP 201 1/051977, respectively).
• the isoxazoline is one or more selected from the group consisting of fluralaner, afoxolaner, lotilaner or sarolaner.
• the compound of Formula (I) is 4-[5-(3,5-Dichlorophenyl)-5- trifluoromethyl-4,5-dihydroisoxazol-3-yl]-2-methyl-A/-[(2,2,2-trifluoro-ethylcarbamoyl)- methyl]-benzamide (CAS RN 864731 -61 -3 - USAN fluralaner).
• the fluralaner is S-fluralaner.
• the compound of Formula (I) is 4-[5-[3-Chloro-5- (trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2- trifluoroethyl)amino]ethyl]-1 -naphthalenecarboxamide (CAS RN 1093861 -60-9, USAN - afoxolaner) that was disclosed in WO2007/079162.
• the isoxazoline is lotilaner (CAS RN: 1369852-71 -0; 3-methyl-N-[2-oxo-2 -(2,2,2- trifluoroethylamino)ethyl]-5-[(5S)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4H-1 ,2- oxazol-3-yl]thiophene-2-carboxamide).
• the isoxazoline is sarolaner (CAS RN: 1398609-39-6; 1 -(5'-((5S)-5-(3,5-dichloro-4- fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-3'-H-spiro(azetidine-3,1 '-(2) benzofuran)-1 -yl)-2-(methylsulfonyl) ethanone).
• the compound of Formula (I) is (Z)-4-[5-(3,5-Dichlorophenyl)-5- trifluoromethyl-4,5-dihydroisoxazol-3-yl]-N-[(methoxyimino)methyl]-2-methylbenzamide (CAS RN 928789-76-8).
• the compound of Formula (I) is 4-[5-(3,5-dichlorophenyl)-5- (trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-N-(thietan-3-yl)benzamide (CAS RN).
• the compound according to the invention is 5-[5-(3,5- Dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-3-methyl-N-[2-oxo-2- [(2,2,2-trifluoroethyl)amino]ethyl]- 2-thiophenecarboxamide (CAS RN: 1231754-09-8), which was disclosed in WO 2010/070068.
• An embodiment of the invention is a process for preparing isoxazoline compound particles wherein the isoxazoline compound is a compound of Formula (I) comprising a) Combining an isoxazoline compound in a crystallizer vessel with a solvent which has a temperature dependent solubility of the isoxazoline compound; b) Heating the crystallizer vessel until the isoxazoline compound is dissolved in the solvent; c) Cooling the crystallizer vessel to 48-55°C to form a batch of supersaturated isoxazoline compound in the solvent; i) adding crystalline seed of the isoxazoline compound to the crystallizer vessel to initiate crystallization and particle growth; ii) Forming a slurry of isoxazoline compound particles and solvent in the crystallizer vessel; d) Maintaining the temperature of the crystallizer vessel to 48-55°C; e) Removing a portion of the batch and heating the removed portion to fully dissolve the isoxazoline compound particles in the solvent; wherein the rate
• the isoxazoline compound is fluralaner.
• the solvent is methanol or acetone. In yet another embodiment, the solvent is an acetate or acetonitrile. In an embodiment, the solvent is selected from the group of dimethyl acetamide (DMA), N-methylpyrrolidone (NMP), dimethyl sulfoxide (DMSO), N,N-diethy-m-toluamide (DEET), 2-pyrrolidone, acetone, g-hexalactone, glycofurol (tetraglycol), methyl ethyl ketone, diethylene glycol monoethyl ether (Transcutol®), ethyl lactate, dimethylisosorbide, ethyl acetate, macrogol glycerol caprylcaprate (Labrasol®), dipropylene glycol monomethyl ether (DowanolTM DPM), glycerol formal, benzyl alcohol, methanol, polyethylene glycol 200, propylene carbonate, 1 -methoxy-2-
• the solvent is isopropanol.
• the solvent is a mixture of toluene and ethyl acetate.
• the crystallizer of step b is heated to a temperature greater than 60°C, preferably about 65 °C.
• step c) the crystallizer vessel is cooled to achieve supersaturation, preferably to a temperature of about 48-55°C, more preferably to a temperature of about 52-54°C.
• the removed portion is heated to a temperature greater than 60°C, preferably about 65 °C.
• the removed portion is heated via a heat exchanger or in a second vessel.
• the rate of removal in step e) is 0.40 to 0.46 batch volumes per hour.
• the rate of removal is maintained for about 4 to 24 hours, preferably about 6 hours.
• the crystallizer vessel of step g) is cooled to a temperature of around 0°C or less, preferably about -10 °C.
• thermoelectric filtering further comprising a step of filtering the isoxazoline compound particles of step g).
• the temperature of the filtering is maintained at a temperature of 0°C or less, preferably at -10 °C.
• the filtered isoxazoline particles are dried.
• Embodiments of the invention are the isoxazoline compound particles produced by any of processes disclosed herein.
• An embodiment of the invention is a isoxazoline compound particle composition
• a isoxazoline compound particle composition comprising particles with a thickness of greater than 10pm, preferably greater than 20pm as measured by scanning electron microscopy (SEM), and a mechanical resiliency as measured by a pressure titration using the Sympatec HELOS, wherein the particle size distribution (d50) of the particles does not decrease by more than 40% from 1 to 3 bar dispersion pressure.
• the particle size distribution (d50) of the particles does not decrease by more than 35% from 1 to 3 bar dispersion pressure.
• the particle size distribution (d50) of the particles does not decrease by more than 30% from 1 to 3 bar dispersion pressure.
• the isoxazoline compound particle composition comprising particles with a thickness of greater than 10pm but less than 100 pm, preferably greater than 20pm but less than 90 pm, preferably greater than 30pm but less than 80 pm as measured by scanning electron microscopy (SEM). In an embodiment, the isoxazoline compound particle composition comprising particles with a thickness of greater than 10pm, preferably greater than 20pm.
• the isoxazoline compound has a particle size distribution of D50 as measured by a static light scattering instrument of from about 25 microns to about 250 microns, particle size of from about 1 1 microns to about 250 microns, particle size of from about 50 microns to about 150 microns, particle size of from about 75 microns to about 125 microns, particle size of from about 75 microns to about 150 microns, particle size of from about 90 microns to about 1 10 microns or a particle size of from about 30 microns to about 100 microns.
• Particle size distribution describes the relative amount of particles present according to size.
• D10 is a particle size distribution that expresses the size that 10 % of the particles are smaller than.
• D50 is a particle size measurement distribution that expresses the size that 50 % of the particles are smaller than.
• D90 is a particle size measurement distribution that expresses the size that 90 % of the particles are smaller than.
• the D10 of particle size is about 10 ⁇ , about 20 ⁇ , about 30 ⁇ , about 40 ⁇ , about 50 ⁇ , about 60 ⁇ , or about 80 ⁇ .
• the D50 of particle size is about 50 ⁇ , about 75 ⁇ , about 80 ⁇ , about 90 ⁇ , about 100 ⁇ , about 1 10 ⁇ , about 120 ⁇ , about 130 ⁇ about 140 ⁇ or about 150 ⁇ .
• the D90 of particle size is about 100 ⁇ , about 130 ⁇ , about 150 ⁇ , about 175 ⁇ , about 200 ⁇ , or about 250 ⁇ .
• the D10 of the particle size is about 20 to 35 ⁇
• the D50 of the particle size is about 90 to 105 ⁇
• the D90 of the particle size is about 155 to 175 ⁇ .
• the D10 of the particle size is about 25 to 30 ⁇
• the D50 of the particle size is about 95 to 100 ⁇
• the D90 of the particle size is about 160 to 170 ⁇ .
• the D10 of the particle size is about 10 to 20 ⁇
• the D50 of the particle size is about 85 to 1 10 ⁇
• the D90 of the particle size is about 170 to 185 ⁇ .
• the D10 of the particle size is about 10 to 15 ⁇
• the D50 of the particle size is about 95 to 105 ⁇
• the D90 of the particle size is about 175 to 180 ⁇ .
• the D10 of the particle size is about 10 to 25 ⁇
• the D50 of the particle size is about 40 to 60 ⁇
• the D90 of the particle size is about 95 to 100 ⁇ .
• the D10 of the particle size is about 15 to 20 ⁇
• the D50 of the particle size is about 45 to 55 ⁇
• the D90 of the particle size is about 90 to 95 ⁇ .
• the D10 of the particle size is about 30 to 50 ⁇ and the D50 of the particle size is about 70 to 130 ⁇ .
• the D10 of the particle size is about 35 to 45 ⁇ and the D50 of the particle size is about 90 to 1 10 ⁇ .
• the D10 of the particle size is about 40 ⁇ and the D50 of the particle size is about 100 ⁇ .
• the volume weighted particle size can be measured by sieving, microscopy or laser diffraction (Malvern or Sympatec)
• the volume weighted particle size measurement can be performed with a Malvern Mastersizer 2000 with the Hydro 2000G measuring cell, or with a Horiba LA-910 laser scattering particle size distribution analyzer.
• the volume weighted particle size can be measured by a Sympatec Helos instrument.
• the isoxazonline compound is fluralaner.
• Example 1 Process to form large particle size fluralaner
• Fluralaner was added at a concentration of 100mg/ml_ in I PA, with 60g added to 600ml_ of isopropanol. This composition was heated to 65°C over 1 hour, and aged for one hour to ensure full dissolution. The solution was cooled over 20 minutes to 50°C and seeded with 0.6g of crystalline fluralaner seed. The batch was further cooled to 20°C over two hours to establish the starting particles. The batch was heated to 54°C, at which point a stream of the batch was removed and heated to an elevated temperature until fully dissolved (>65°C). The removal rate and return rate to the crystallizer were set to approximately 4.4-4.8ml_/min.
• the recycle loop continued for 6 hours, at which point the x50 particle size dimension is approximately 40 ⁇ .
• the batch was aged at 54°C for 6 hours to further relieve supersaturation, then cooled to 45°C over 6 hours, and further cooled to 0°C over 16 hours. See Figure 3 for a schematic of the process equipment.
• the resultant slurry was filtered and dried to produce fluralaner particles.
• the dried fluralaner particles were measured to determine the particle dimensions and mechanical resiliency.
• Example 2 Determination of the particle size and mechanical resiliency of the fluralaner particles.
• Figure 5 shows the results of the pressure titration experiment.
• the particle size distribution was monitored as the particles are exposed to increasing pressure from 1 bar to 3 bar.
• Figure 5 shows that as the pressure increased, the median particle size (d50) decreases from 1 10 ⁇ to 60 ⁇ , a loss of around 45%.
• the particle size distribution curve broadens and shifts towards smaller particle sizes. This is evidence that these particles are being broken under the increased pressure and is an indication that the particles were very thin.
• Figure 10 shows the particle size distribution of the fluralaner crystals produced by the inventive process. These particles have a larger d50 than the particles of Figure 5. Furthermore, in the pressure titration test, for the particles produced by the inventive process, the d50 was reduced by only around 25% of the original value. This is an indication of the increased mechanical resiliency of these particles. Also of note is the fact that under the elevated pressures, the distribution does not broaden in the same fashion as the particles from the unoptimized process shown in Figure 5.
• Figure 7 shows the particle size distribution and pressure titration of an additional batch of fluralaner particles that were produced by the inventive process. In this case, the original d50 of around 103 ⁇ was reduced to around 67 ⁇ , a loss of around 35%.
• Figure 8 is a scanning electron microscopy image of fluralaner particles that were not produced the inventive process. Of note is that these crystals are rather thin.
• Figure 9 is a scanning electron microscopy image of fluralaner partices that were produce by the inventive process. In contrast to the particles shown in Figure 8, these particles are large (around 100 ⁇ ) and thick (around 10-20 ⁇ ).
• Example 3 - Process to form large particle size fluralaner at the 6L scale: Fluralaner was added at a concentration of 100mg/ml_ in isopropanol ( I PA), with 600g added to 6L of isopropanol. This composition was heated to 65°C over 1 hour, and aged for one hour to ensure full dissolution. The solution was cooled over 20 minutes to 50°C and seeded with 6g of crystalline fluralaner seed, in this instance unmilled seed with an d50 of approximately 10 ⁇ . The batch was further cooled to 20°C over two hours to establish the starting particles.
• I PA isopropanol
• the batch was heated to 54°C, at which point 1.2L of the batch was removed and heated to an elevated temperature until all solids were fully dissolved (>65°C).
• a recirculation loop was then started, with the removal rate and return rate to the crystal I izer set to approximately 44-48ml_/min.
• the recycle loop continued for 3 hours, at which point the d50 particle size dimension is approximately 45 ⁇ .
• the batch was aged at 54°C for 6 hours to further relieve supersaturation, then cooled to 45°C over 6 hours, and further cooled to 0°C over 16 hours.
• the resultant slurry was filtered and dried to produce fluralaner particles.
• the dried fluralaner particles were measured to determine the particle dimensions and inform mechanical resiliency of the particles, and shown in Figure 10. See figure 1 1 for an SEM image of the resulting particles.
• Example 4 - Process to form large particle size fluralaner at the pilot scale:
• Fluralaner was added at a concentration of 100mg/ml_ in I PA, with 60kg added to 600L of isopropanol. This composition was heated to 65°C over 1 hour, and aged for one hour to ensure full dissolution. The solution was cooled over 20 minutes to 50°C and seeded with 600g of crystalline fluralaner seed, again with unmilled seed crystals having an d50 of approximately 10 ⁇ . The batch was further cooled to 20°C over two hours to establish the starting particles. The batch was heated to 54°C, at which point 120L of the batch was removed and heated to an elevated temperature until fully dissolved (>65°C). The removal rate and return rate to the crystal I izer were set to approximately 4.4-4.8L/min.
• the recycle loop continued for 2.75 hours, at which point the d50 particle size dimension is approximately 40 ⁇ .
• the batch was aged at 54°C for 6 hours to further relieve supersaturation, then cooled to 45°C over 6 hours, and further cooled to 0°C over 16 hours.
• See Figure 12 for a schematic of the process equipment.
• the resultant slurry was filtered and dried to produce fluralaner particles. Agitation was limited during the filtration and drying.
• the material was delumped at low speed in a conical mill.
• the dried fluralaner particles were measured to determine the particle dimensions and mechanical resiliency. See figure 13 for the particle size distribution and mechanical resiliency. See figure 14 for an SEM image of the resulting particles.
• Example 5 - Process to form large particle size fluralaner from an alternative solvent system:
• Fluralaner was added at a concentration of 100mg/ml_ in 5:3 (volume basis) of
• the recycle loop continued for 2.2hours, at which point the x50 particle size dimension is approximately 50 ⁇ .
• the batch was aged at 54°C for 5 hours to further relieve supersaturation, then cooled to 45°C over 6 hours, and further cooled to 0°C over 16 hours.
• the dried fluralaner particles were measured to determine the particle

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Inorganic Chemistry (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Environmental Sciences (AREA)
• Zoology (AREA)
• Pest Control & Pesticides (AREA)
• Plant Pathology (AREA)
• Wood Science & Technology (AREA)
• Agronomy & Crop Science (AREA)
• Dentistry (AREA)
• Tropical Medicine & Parasitology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Dermatology (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• Dispersion Chemistry (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Insects & Arthropods (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Priority Applications (21)

Applications Claiming Priority (4)

Related Child Applications (2)

Publications (1)

Family

ID=64172503

Family Applications (1)

Country Status (16)

Cited By (5)

Families Citing this family (1)

Citations (14)

Family Cites Families (10)

• 2018
  • 2018-11-06 CN CN201880071993.8A patent/CN111295375B/zh active Active
  • 2018-11-06 AU AU2018363686A patent/AU2018363686B2/en active Active
  • 2018-11-06 US US16/761,695 patent/US11858904B2/en active Active
  • 2018-11-06 WO PCT/EP2018/080230 patent/WO2019091940A1/en not_active Ceased
  • 2018-11-06 JP JP2020524272A patent/JP7446222B2/ja active Active
  • 2018-11-06 CA CA3081653A patent/CA3081653A1/en active Pending
  • 2018-11-06 BR BR112020008848-0A patent/BR112020008848A2/pt active Search and Examination
  • 2018-11-06 KR KR1020247026604A patent/KR102819993B1/ko active Active
  • 2018-11-06 PE PE2020000564A patent/PE20210170A1/es unknown
  • 2018-11-06 UA UAA202003421A patent/UA127892C2/uk unknown
  • 2018-11-06 EP EP18799512.1A patent/EP3707129A1/en active Pending
  • 2018-11-06 KR KR1020207015894A patent/KR102694519B1/ko active Active
  • 2018-11-06 MX MX2020004693A patent/MX2020004693A/es unknown
• 2020
  • 2020-04-20 IL IL274075A patent/IL274075A/en unknown
  • 2020-05-04 CL CL2020001172A patent/CL2020001172A1/es unknown
  • 2020-05-22 CO CONC2020/0006258A patent/CO2020006258A2/es unknown
  • 2020-06-01 PH PH12020500586A patent/PH12020500586A1/en unknown
  • 2020-07-13 MX MX2025006001A patent/MX2025006001A/es unknown
  • 2020-07-13 MX MX2023014279A patent/MX2023014279A/es unknown
• 2023
  • 2023-04-24 JP JP2023070584A patent/JP7578752B2/ja active Active
  • 2023-10-20 JP JP2023180745A patent/JP2024010042A/ja active Pending
  • 2023-11-16 US US18/510,718 patent/US20240246921A1/en active Pending
• 2024
  • 2024-02-22 AU AU2024201160A patent/AU2024201160A1/en active Pending

Patent Citations (15)

Non-Patent Citations (10)

Also Published As

Similar Documents

Legal Events